Dr Reddy's Laboratories, a Rs. 14,800 crore plus pharma giant from Hyderabad, has posted strong growth in bottomline during the year ended March 2019 despite pressure on top line. The consolidated net profit went up sharply by 106 per cent to Rs. 1,950 crore from Rs. 947 crore and its basic earnings per share improved to Rs. 117.53 from Rs. 57.08 in the last year. Though the margins improved, the DRL scrip received setback after the announcement of financial working and declined sharply by over 5.8 per cent to Rs. 2,588 on BSE on May 20, 2019 with market capitalization of Rs. 44,194 crore. The scrip touched to its yearly high level at Rs. 2,965 on May 2, 2019 as it started moving from yearly lowest level of Rs. 1,888 on May 21, 2018
Amneal`s Generic Oxaprozin Receives Approval In US